Reviewed August 2026 by the Corydalis Labs Technical Team. How we research and review.
The observation
Pick up six products from six brands. Read the ingredient panels. In most cases you are holding the same active in the same format at a similar strength, and the entire difference between them is design, price, and whatever the front of the pack promises.
Brands know this. It is why so much energy in this category goes into packaging, influencer spend, and distribution deals — those are the levers left when the product itself is a commodity.
Why it happened
Differentiation in a consumable comes from the formula, and formula differentiation needs ingredients. This category has had a narrowing supply of them.
The kratom leaf gives you mitragynine and a set of minor alkaloids. Everything the category reached for beyond that — 7-OH, pseudoindoxyl, the MGM compounds — was a derivative of the same chemistry, and each one has come under regulatory action. The full sequence.
What is left is the base alkaloid everyone already has. When every brand has access to the same single active, the products converge. That is not a moral failing; it is what a commodity input does to a category.
What the sameness costs a brand
- Price becomes the axis. When a customer cannot perceive a difference, the cheapest option is rational.
- Retailer relationships get fragile. A buyer with eight interchangeable options has no reason to protect any of them, and every reason to negotiate.
- Marketing gets riskier. Brands that cannot differentiate on formula tend to differentiate on claims, and claims are precisely where enforcement in this category lands. The sameness is upstream of a lot of the regulatory trouble.
- Loyalty does not form. If the product is the same, the switching cost is zero.
The two ways out
There are only two, and they are structurally different.
1. Add something the shelf does not have
Something that changes the finished product in a way a customer can perceive. The constraint is that it has to be an ingredient with a durable position — otherwise you are buying a differentiator with an expiry date, which is what the category has done three times already.
The test we would apply to any candidate: does its parent chemistry have a scheduling history? Ours does not, and we have written down why rather than asking anyone to take it on faith. The reasoning.
2. Leave the shelf
Build something with no kratom in it at all, for channels the category cannot currently reach — retailers who declined kratom as policy, states that prohibit it, and the alcohol-alternative category. That is a different product for a different customer rather than a better version of what you sell now. The kratom-free path.
Most brands we work with eventually do both, because they solve different problems.
The honest caveat
We supply 13-OH Corydalis Yanhusuo, so read the above knowing where it comes from.
Two things we would say against our own interest. First, 13-OH is a synergist, not a primary active. It will not carry a product on its own at commercial inclusion rates and it does not reproduce the profile of anything that has been scheduled. Brands hoping for a drop-in replacement are going to be disappointed, and we would rather they hear it here than after buying a kilogram.
Second, differentiation is not only an ingredient problem. Format, flavour, pack, price architecture, and the story all differentiate too, and they are cheaper. If your product is undifferentiated because everything about it is generic, a new active will not fix that.
What an ingredient can do is give you something true to say that your competitors cannot say. That is worth a great deal in a category where everyone is currently saying the same thing.